Leveraging Health Department Capacities, Partnerships, and Health Insurance for Infectious Disease Response in Massachusetts, 2014-2018.
We describe the efforts of the Massachusetts Department of Public Health to integrate its HIV, viral hepatitis, sexually transmitted infection (STI), and tuberculosis response through policies that mandated contracted organizations to submit specimens for testing to the Massachusetts State Public Health Laboratory; co-test blood specimens for HIV, hepatitis C virus (HCV), and syphilis; integrate HIV, viral hepatitis, and STI disease surveillance and case management in a single data system; and implement an integrated infectious disease drug assistance program. From 2014 through 2018, the number of tests performed by the Massachusetts State Public Health Laboratory increased from 16 321 to 33 674 for HIV, from 11 054 to 33 670 for HCV, and from 19 169 to 30 830 for syphilis. Service contracts enabled rapid response to outbreaks of HIV, hepatitis A, and hepatitis B. Key challenges included lack of a billing infrastructure at the Massachusetts State Public Health Laboratory; the need to complete negotiations with insurers and to establish a retained revenue account to receive health insurance reimbursements for testing services; and time to train testing providers in phlebotomy for required testing. Investing in laboratory infrastructure; creating billing mechanisms to maximize health insurance reimbursement; proactively engaging providers, community members, and other stakeholders; and building capacity to transform practices are needed...
Publication date: Available online 10 October 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Pramod Kumar, Anand Kulkarni, Mithun Sharma, Padaki Nagaraja Rao
[This Day] Asaba -- Delta State Government has launched the HIV Self-Testing Programme with a vow to scale up all response measures for arresting the relatively high HIV prevalence rate in the state, which places Delta as being among the highest in the country.
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Trump plans in-person rally on Monday as next presidential debate cancelled; Europe records 100,000 daily cases for first time; Canada at ‘tipping point’. Follow latest updatesEurope: Spain declares emergency in Madrid as Berlin emerges as hotspotUK workers to get two-thirds of wages if firms told to shutAustralia: Is Victoria ready to come out of lockdown?US presidential debate cancelled – live updatesSee all our coronavirus coverage5.42amBSTMy colleagueLuke Henriques-Gomes has this story giving you a summary of the main Covid-19 stories from Australia.A main point of the day has beenVictoria ’s pr...
Publication date: 10–16 October 2020Source: The Lancet, Volume 396, Issue 10257Author(s): Talha Burki
Publication date: Available online 9 October 2020Source: Microbiological ResearchAuthor(s): M.A. Abo-Kadoum, Mohammed Assad, Yongdong Dai, Nzungize Lambert, Ulrich Aymard Ekomi Moure, Adel Eltoukhy, Stech A.E. Nazou, Asmaa Moaaz, Jianping Xie